Alemtuzumab

Drug Profile

Alemtuzumab

Alternative Names: Anti-CD52 monoclonal antibody; Campath; Campath-1H; LDP-03; Lemtrada; MabCampath; MabKampat; Remniq

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Cambridge
  • Developer Bayer HealthCare Pharmaceuticals Inc.; Dana-Farber Cancer Institute; German CLL Study Group; Ohio State University Comprehensive Cancer Center; Sanofi; Sanofi Oncology; University of Cologne
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD52 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Multiple sclerosis
  • Phase II T cell prolymphocytic leukaemia
  • Phase I Diffuse large B cell lymphoma; Lymphoma; T cell lymphoma
  • No development reported Graft-versus-host disease
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, Second-line therapy or greater) in USA (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Graft-versus-host-disease in USA (IV, Infusion)
  • 27 Oct 2017 Additional efficacy data from the extension trials of CARE-MS-I and CARE-MS-II released by Sanofi Genzyme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top